Cos (e.g., Cos-7, Etc.) Patents (Class 435/365)
Expressing recombinant lymphokine, interferon, hormone, growth factor or morphogen (Class 435/365.1)
-
Patent number: 10376539Abstract: Disclosed are methods of inhibiting progression, stabilizing and reversing amyotrophic lateral sclerosis and neuromuscular degenerative diseases including spinal muscular atrophy, by administration of xenon, or noble gas compositions at a sufficient frequency and concentration to evoke anti-inflammatory, immunomodulatory, and regenerative processes in a patient in need of therapy. In one embodiment, xenon is administered as a pharmaceutical preparation at a concentration of 5 to 90% by volume, more preferably for certain embodiments, at 5 to 30% by volume, wherein said pharmaceutical preparation additionally contains oxygen, argon, nitrogen and/or air. In other embodiments argon is utilized together, or as a replacement for xenon. Furthermore, the use of xenon and/or other noble gas combinations are disclosed for augmentation of therapies that augment endogenous regenerative cells.Type: GrantFiled: May 17, 2017Date of Patent: August 13, 2019Assignee: Nobilis Therapeutics, Inc.Inventors: Vlad Bogin, Thomas Ichim, Santosh Kesari
-
Patent number: 9952216Abstract: Herein are described a set of novel specific human enhancers for specific forebrain cell types used to study and select for human neural progenitor cells. This approach enables the ability to generate interneurons from human ES, iPS and iN cells, making them available for human transplantation and for molecular/cellular analyzes. These approaches are also directly applicable to generating other neuronal cell types, such as cortical and striatal projection neurons, which have implications for many human diseases.Type: GrantFiled: October 10, 2014Date of Patent: April 24, 2018Assignee: The Regents of the University of CaliforniaInventors: Axel Visel, John L. R. Rubenstein, Ying-Jiun (Jasmine) Chen, Len A. Pennacchio, Daniel Vogt, Cory Nicholas, Arnold Kriegstein
-
Patent number: 9486494Abstract: This invention provides novel peptides and methods to prevent, control, and treat an inflammation, cancer and other disorders, particularly of the gastrointestinal tract and the lung by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound selected from i) 5-aminosalicyclic acid (5-ASA) or a derivative or a pharmaceutically acceptable salt thereof; ii) mercaptopurine; or iii) an anti-TNF therapy.Type: GrantFiled: March 13, 2014Date of Patent: November 8, 2016Assignee: SYNERGY PHARMACEUTICALS, INC.Inventor: Kunwar Shailubhai
-
Publication number: 20150147349Abstract: This invention relates to compositions and methods for eliciting an immune response against a parasite of the genus Plasmodium in a mammal.Type: ApplicationFiled: February 15, 2013Publication date: May 28, 2015Inventors: Timothy A. Springer, Chafen Lu, Gaojie Song, Adem Koksal
-
Publication number: 20150147332Abstract: An isolated protein or peptide selected from the group consisting of Bordetella colonization factor A (BcfA) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.Type: ApplicationFiled: September 26, 2014Publication date: May 28, 2015Inventors: Rajendar K. Deora, Meenu Mishra, Neelima Sukumar
-
Publication number: 20150139953Abstract: Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.Type: ApplicationFiled: January 16, 2015Publication date: May 21, 2015Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
-
Publication number: 20150132330Abstract: Provided herein are flu hemagglutinin polypeptides, including chimeric influenza virus hemagglutinin polypeptides, and flu hemagglutinin polypeptides comprising modified glycosylation sites and non-naturally glycosylation sites, compositions comprising the same, vaccines comprising the same and methods of their use.Type: ApplicationFiled: September 19, 2012Publication date: May 14, 2015Inventors: Adolfo Garcia-Sastre, Peter Palese, Florian Krammer, Natalie Pica, Dirk Eggink, Rafael A. Medina-Silva, Rong Hai
-
Publication number: 20150133379Abstract: The present invention relates to a fusion protein comprising a skin-penetrating peptide, a polynucleotide encoding the fusion protein, an expression vector comprising the polynucleotide, a transformant comprising the expression vector, a method for preparing the fusion protein, a cosmetic composition for improving skin conditions, which comprises the fusion protein, and a pharmaceutical composition for external skin use, which comprises the fusion protein. The fusion protein of the invention comprises a skin-penetrating peptide bound to a physiologically active protein. The fusion protein significantly enhances the skin penetration and skin retention of the physiologically active protein while maintaining or enhancing the ability of the physiologically active protein to synthesize a material showing physiologically active effects. Thus, it can be widely used as an active ingredient in functional cosmetic compositions and pharmaceutical compositions for external skin use.Type: ApplicationFiled: April 30, 2014Publication date: May 14, 2015Inventors: Seol Hoon Lee, Sang Hwa Lee, Nae Gyu Kang, Eu Gene Hur
-
Publication number: 20150125893Abstract: The invention provides fusion proteins comprising at least one fluorescent protein that is linked to at least one transporter protein that changes three-dimensional conformation upon specifically transporting its substrate. The transporter protein may be a nitrate transporter, a peptide transporter, or a hormone transporter. The invention provides fusion proteins comprising at least one fluorescent protein that is linked to at least one mechanosensitive ion channel protein. The invention also provides for methods of using the fusion proteins of the present invention and nucleic acids encoding the fusion proteins.Type: ApplicationFiled: November 6, 2014Publication date: May 7, 2015Inventors: Wolf B. Frommer, Cheng-Hsun Ho
-
Publication number: 20150111233Abstract: Luciferases which are different from those known heretofore have been desired. A luciferase mutant comprising an amino acid sequence in which at least one amino acid selected from the group consisting of valine at the position of 44, alanine at the position of 54 and tyrosine at the position of 138 is substituted with other amino acid(s) in the amino acid sequence of SEQ ID NO: 2.Type: ApplicationFiled: October 17, 2014Publication date: April 23, 2015Inventors: Satoshi INOUYE, Junichi SATO
-
Publication number: 20150110825Abstract: The present invention provides nanoparticles and compositions of various constructs that combine meta-stable viral proteins (e.g., RSV F protein) and self-assembling molecules (e.g., ferritin, HSPs) such that the pre-fusion conformational state of these key viral proteins is preserved (and locked) along with the protein self-assembling into a polyhedral shape, thereby creating nanoparticles that are effective vaccine agents. The invention also provides nanoparticles comprising a viral fusion protein, or fragment or variant thereof, and a self-assembling molecule, and immunogenic and vaccine compositions including the same.Type: ApplicationFiled: September 24, 2014Publication date: April 23, 2015Inventors: Ram SASISEKHARAN, Aditya RAGURAM, Vidya SUBRAMANIAN
-
Publication number: 20150111222Abstract: The present disclosure provides, inter alia, genetically encoded recombinant peptide biosensors comprising analyte-binding framework portions and signaling portions, wherein the signaling portions are present within the framework portions at sites or amino acid positions that undergo a conformational change upon interaction of the framework portion with an analyte.Type: ApplicationFiled: August 8, 2012Publication date: April 23, 2015Applicant: HOWARD hUGHES MEDICAL INSTITUTEInventors: Jonathan Marvin, Loren Looger, Richard T. Lee, Eric Schreiter
-
Publication number: 20150105315Abstract: The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase or variants thereof possessing endonuclease activity, wherein said PA subunit is from a virus belonging to the Orthomyxoviridae family. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting.Type: ApplicationFiled: October 21, 2014Publication date: April 16, 2015Applicants: EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL), UNIVERSITY JOSEPH FOURIER FILIALE, Centre National de la Recherche Scientifique - Direction de la Politique IndustrielleInventors: Denis Bouvier, Thibaut Crepin, Rob Ruigrok, Alexander Dias, Stephen Cusack
-
Publication number: 20150104450Abstract: Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.Type: ApplicationFiled: March 11, 2013Publication date: April 16, 2015Inventors: Ralph Minter, Julie Douthwaite, Jacques Moisan, Michael Bowen, Steven Rust, Cyril Privezentzev
-
Publication number: 20150098956Abstract: Recombinant polypeptides comprising a DR?1 domain, an antigenic peptide, and a linker sequence are disclosed. The linker sequence comprises a first glycine-serine spacer, a thrombin cleavage site and a second glycine-serine spacer. Further disclosed are pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides.Type: ApplicationFiled: October 3, 2014Publication date: April 9, 2015Inventors: Arthur A. Vandenbark, Roberto Meza-Romero, Gil Benedek, Gregory G. Burrows
-
Publication number: 20150094271Abstract: A leucine zipper variant, a polynucleotide encoding the leucine zipper variant, a method of preparing a leucine zipper variant, a method of inhibiting HDM2- and/or HDMX using the leucine zipper variant, and a method of the prevention and/or treatment of cancer using the leucine zipper variant.Type: ApplicationFiled: September 30, 2014Publication date: April 2, 2015Inventors: Jung-Hoon Lee, Eunji Kang, Hye Yoon Kang, Dongkyu Shin, Jae Il Lee, Jieun Han, Jung Min Lee
-
Publication number: 20150094450Abstract: The present invention relates to an repebody capable of binding specifically to interleukin-6 (IL-6) to inhibit the biological activity of IL-6, a polynucleotide encoding the repebody, a vector comprising the polynucleotide, a recombinant microorganism having introduced therein the polynucleotide or the vector, a method of producing the repebody using the recombinant microorganism, a composition for preventing or treating cancer, which comprises the repebody, and a method for preventing or treating cancer, which comprises administering the composition for preventing or treating cancer, which comprises the repebody. The repebody of the present invention significantly reduces the activity of STAT3 and the concentration of interleukin-6, and thus can be widely used as an agent for preventing or treating IL-6-related diseases.Type: ApplicationFiled: February 27, 2013Publication date: April 2, 2015Applicants: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY, THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC), KOREA BASIC SCIENCE INSTITUTEInventors: Hak-Sung Kim, Joong-Jae Lee, Jung Min Choi, Eun-Kyeong Jo, Chul-Su Yang, Hae-Kap Cheong, Hyun Jung Kim
-
Publication number: 20150087596Abstract: The present invention relates to Huwentoxin-IV variants, polynucleotides encoding them, methods of making and using the foregoing, and methods of alleviating pain with peptide inhibitors of Nav1.7.Type: ApplicationFiled: March 15, 2013Publication date: March 26, 2015Inventors: William Eckert, Mack Flinspach, Michael Hunter, Yi Liu, Robert Neff, Alan Wickenden, Alan Gibbs
-
Publication number: 20150087604Abstract: The present invention relates to a polypeptide that is capable of inhibiting transcription and expression of fatty acid synthase (FAS) and the polynucleotides encoding therefor, as well as the use thereof. Specifically, the present invention relates to a polypeptide that can inhibit the transcription and expression of FAS at the molecular level, the cellular level and in vivo, and can therefore prevent the overexpression of FAS. Said polypeptide and related peptidomimetics, including functional fragments or functional varieties thereof, and the genes encoding therefor, can be widely used in preventing and treating tumors such as liver cancer, and diseases closely related to the metabolism of fatty acid synthase, such as fatty liver and obesity.Type: ApplicationFiled: April 16, 2012Publication date: March 26, 2015Inventors: Xiaodong Zhang, Lihong Ye
-
Publication number: 20150072353Abstract: Analyte sensors, methods for producing and using analyte sensors, methods of detecting and/or measuring analyte activity, detecting pH change, and/or, controlling the concentration of an analyte in a system, are disclosed. Embodiments of the analyte sensors according to the disclosure can provide an accurate and convenient method for characterizing analyte activity, detecting pH change, controlling the concentration of an analyte in a system, and the like, in both in vivo and in vitro environments, in particular in living cell imaging.Type: ApplicationFiled: August 21, 2014Publication date: March 12, 2015Inventors: Jenny Jie Yang, Shen Tang
-
Publication number: 20150071858Abstract: The present invention relates to the use of p11 as a drug target as well as a tool for the diagnosis, treatment and development of p11/5-HT receptor related disorders. The invention further relates to p11 knock-out animals as well as p11 transgenic animals and their use as models for the development of novel psychotherapeutic agents, and to methods of diagnosis, prophylaxis and treatment of p11/5-HT receptor related disorders.Type: ApplicationFiled: August 5, 2014Publication date: March 12, 2015Inventors: Per SVENNINGSSON, Paul GREENGARD
-
Publication number: 20150071883Abstract: The invention provides improved adeno-associated virus (AAV) Factor VIII (FVIII) vectors, including AAV FVIII vectors that produce a functional Factor VIII polypeptide and AAV FVIII vectors with high expression activity.Type: ApplicationFiled: September 10, 2014Publication date: March 12, 2015Inventor: Peter Cameron Colosi
-
Publication number: 20150072383Abstract: The present disclosure provides engineered transaminase polypeptides for the production of amines, polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to prepare compounds useful in the production of active pharmaceutical agents. The present disclosure provides engineered polypeptides having transaminase activity, polynucleotides encoding the polypeptides, methods of the making the polypeptides, and methods of using the polypeptides for the biocatalytic conversion of ketone substrates to amine products. The present enzymes have been engineered to have one or more residue differences as compared to the amino acid sequence of the naturally occurring transaminase of Vibrio fluvialis. In particular, the transaminases of the present disclosure have been engineered for efficient formation of chiral tryptamine derivatives from its corresponding prochiral ketone substrates.Type: ApplicationFiled: March 22, 2013Publication date: March 12, 2015Inventors: Jovana Nazor, Derek Smith, Michael Crowe, Shiwei Song, Steven J. Collier
-
Publication number: 20150065560Abstract: The present invention relates to a one-vector expression system comprising a sequence encoding two polypeptides, such as tyrosine hydroxylase (TH) and GTP-cyclohydrolase 1 (GCH1). The two polypeptides can be should preferentially be expressed at a ratio between 3:1 and 15:1, such as between 3:1 and 7:1. The invention is useful in the treatment of catecholamine deficient disorders, such as dopamine deficient disorders including but not limited to Parkinson's Disease. Moreover, the present invention provides a method to deliver the vector construct in order to limit the increased production of the catecholamine to the cells in need thereof.Type: ApplicationFiled: April 1, 2014Publication date: March 5, 2015Inventors: Tomas Björklund, Anders Björklund, Deniz Kirik
-
Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
Patent number: 8961977Abstract: The present invention relates to an anti-idiotypic polypeptide scaffold that includes two or more peptide sequences that mimic a discontinuous epitope of a pathogen that is recognized by or induces formation of a broadly neutralizing antibody. Using a fibronectin FNfn10 scaffold bearing two or more modified discontinuous loops, scaffolds that recognize broadly neutralizing antibodies in vitro and from patient serum have been identified. These scaffolds should induce an immune response or mobilize germline specificities to initiate their affinity maturation.Type: GrantFiled: February 14, 2011Date of Patent: February 24, 2015Assignee: University of RochesterInventors: Stephen Dewhurst, Mark A. Sullivan -
Publication number: 20150050264Abstract: The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases.Type: ApplicationFiled: September 7, 2012Publication date: February 19, 2015Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Denis VIVIEN, Jerome PARCQ, Denis VIVIEN, Jerome PARCQ
-
Publication number: 20150037284Abstract: The present invention relates to a novel Listeria bacteriophage designated ProCC P825. In particular, the present invention relates to the endolysin PlyP825 encoded by the novel phage ProCC P825 and uses of the novel endolysin PlyP825 for controlling Listeria contamination and infection.Type: ApplicationFiled: May 29, 2012Publication date: February 5, 2015Applicant: DSM IP ASSETS B.V.Inventors: Holger Grallert, Julia Lorenz, Anna Scherzinger
-
Publication number: 20150037872Abstract: The present invention relates to a method of selecting a protein variant having modified immunogenicity as compared to the parent protein comprising the steps obtaining antibody binding peptide sequences, using the sequences to localise epitope sequences on the 3-dimensional structure of parent protein, defining an epitope area including amino acids situated within 5 ? from the epitope amino acids constituting the epitope sequence, changing one or more of the amino acids defining the epitope area of the parent protein by genetical engineering mutations of a DNA sequence encoding the parent protein, introducing the mutated DNA sequence into a suitable host, culturing said host and expressing the protein variant, and evaluating the immunogenicity of the protein variant using the parent protein as reference. The invention further relates to the protein variant and use thereof, as well as to a method for producing said protein variant.Type: ApplicationFiled: October 15, 2014Publication date: February 5, 2015Inventors: Erwin Ludo Roggen, Steffen Ernst, Allan Svendsen, Esben Peter Friis, Claus Von Der Osten
-
Publication number: 20150038675Abstract: The purpose of the present invention is to provide: a peptide having an affinity for silicon nitride; a polynucleotide encoding the peptide; an expression vector for expressing the peptide having an affinity for silicon nitride; an expression vector for expressing a peptide fusion protein that comprises the peptide having an affinity for silicon nitride and a target protein; a transformant obtained by introducing the expression vector into a host cell; a peptide fusion protein obtained from the transformant; a silicon nitride substrate to which a peptide having an affinity for silicon nitride has been bonded; a method for immobilizing a target protein to a silicon nitride substrate; a composition for immobilizing a target protein to a silicon nitride substrate, the composition comprising a peptide having an affinity for silicon nitride; and a linker for immobilizing a target protein to a silicon nitride substrate, the linker comprising a peptide having an affinity for silicon nitride.Type: ApplicationFiled: February 12, 2013Publication date: February 5, 2015Inventors: Yoichi Kumada, Michimasa Kishimoto, Takeru Otsuka
-
Publication number: 20150023995Abstract: The present invention provides polypeptides having a composite amino acid sequence derived from a consensus sequence representing the capsid proteins of two or more circulating strains of a non-enveloped virus. In particular, the invention provides virus-like particles comprising at least one composite polypeptide. Such virus-like particles have antigenic epitopes of two or more circulating strains of a non-enveloped virus and produce an increase in antisera cross-reactivity to one or more circulating strains of the non-enveloped virus. Methods of making composite virus-like particles and vaccine formulations comprising composite virus-like particles are also disclosed.Type: ApplicationFiled: July 25, 2014Publication date: January 22, 2015Applicant: TAKEDA VACCINES, INC.Inventors: Charles RICHARDSON, Robert F. BARGATZE, Joel HAYNES, Bryan STEADMAN
-
Publication number: 20150017695Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds.Type: ApplicationFiled: September 30, 2014Publication date: January 15, 2015Inventors: Jack Liang, Stephane J. Jenne, Emily Mundorff, Charlene Ching, John M. Gruber, Anke Krebber, Gjalt W. Huisman
-
Publication number: 20150018522Abstract: Disclosed are mutants of galactosyltransferases that can catalyze formation of oligosaccharides in the presence of magnesium; mutants of galactosyltransferases having altered donor and acceptor specificity which can catalyze formation of oligosaccharides in the presence of magnesium; methods and compositions that can be used to synthesize oligosaccharides; methods for increasing the immunogenicity of an antigen; and methods to stabilize platelets.Type: ApplicationFiled: March 10, 2014Publication date: January 15, 2015Applicant: The United States of America, as represented by the Secretary, Department of Health & Human ServicInventors: Pradman K. Qasba, Elizabeth Boeggeman, Boopathy Ramakrishnan
-
Publication number: 20150020221Abstract: The invention provides methods and compositions for enhancing the efficacy of cancer therapies through modulation of BAL1 and/or BBAP. Also provided are methods for predicting the efficacy of cancer therapies or treating cancer in a subject through modulation of BAL1 and/or BBAP. Further provided are methods for identifying compounds that are capable of modulating BAL1-BBAP complexes.Type: ApplicationFiled: October 5, 2012Publication date: January 15, 2015Inventors: Margaret A. Shipp, Qingsheng Yan
-
Publication number: 20150010532Abstract: The invention relates to recombinant nucleic acid and polypeptides encoding collagenase I and collagenase II, methods for the preparation thereof and methods for the use thereof. The invention also encompasses methods related to releasing a composition comprising collagenase prior to therapeutic administration.Type: ApplicationFiled: July 11, 2014Publication date: January 8, 2015Inventor: Wayne K. Herber
-
Publication number: 20150005177Abstract: Provided here are new methods to identify specific families of mammalian odorant receptors for odorants or aroma, particularly indole and skatole malodors and their use in assays that may be used to discover compounds that modulate (blocking, enhancing, masking or mimicking compounds) their activity. Orphan mouse odorant receptors are identified from olfactory sensory neurons that respond to target compounds. The resulting receptors as well as their human counterparts can be screened in assays against test compounds to confirm their identity as odorant or aroma receptors, particularly malodor receptors and subsequently discover for example modulators that inhibit the perception of the malodor in humans.Type: ApplicationFiled: June 28, 2014Publication date: January 1, 2015Applicant: FIRMENICH SAInventors: Patrick PFISTER, Matthew E. ROGERS, Khalid Jerod PARRIS
-
Publication number: 20140377800Abstract: The present invention relates to methods of optimization of a protein coding sequences for expression in a given host cell. The methods apply genetic algorithms to optimise single codon fitness and/or codon pair fitness sequences coding for a predetermined amino acid sequence. In the algorithm generation of new sequence variants and subsequent selection of fitter variants is reiterated until the variant coding sequences reach a minimum value for single codon fitness and/or codon pair fitness. The invention also relates to a computer comprising a processor and memory, the processor being arranged to read from and write into the memory, the memory comprising data and instructions arranged to provide the processor with the capacity to perform the genetic algorithms for optimisation of single codon fitness and/or codon pair fitness.Type: ApplicationFiled: May 20, 2014Publication date: December 25, 2014Inventors: Johannes Andries ROUBOS, Noel Nicolaas Maria Elisabeth VAN PEIJ
-
Publication number: 20140377407Abstract: This invention relates to a novel alpha-amylase, a process for its preparation and the use of the amylase. The invention relates to a newly identified polynucleotide sequence from Alicyclobacillus pohliae comprising a gene that encodes the novel alpha-amylase enzyme. The invention features the full length coding sequence of the novel gene as well as the amino acid sequence of the full-length functional protein of the gene. The invention also relates to methods of using these proteins in industrial processes, for example in food industry, such as the baking industry. Also included in the invention are cells transformed with a polynucleotide according to the invention suitable for producing these proteins and cells.Type: ApplicationFiled: January 29, 2013Publication date: December 25, 2014Applicant: DSM IP ASSETS B.V.Inventor: Lucie Parenicova
-
Patent number: 8911776Abstract: The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue.Type: GrantFiled: October 26, 2012Date of Patent: December 16, 2014Inventor: Claresa Levetan
-
Publication number: 20140356346Abstract: The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.Type: ApplicationFiled: May 15, 2014Publication date: December 4, 2014Applicant: CSL Behring GmbHInventors: Thomas WEIMER, Stefan SCHULTE, Ulrich KRONTHALER, Wiegand LANG, Uwe LIEBING, Wilfried WORMSBÄCHER
-
Publication number: 20140357564Abstract: The present invention relates to a polypeptide comprising a modified von Willebrand Factor (VWF) having a higher Factor VIII binding affinity than non-modified VWF, its pharmaceutical use and method of its preparation.Type: ApplicationFiled: February 14, 2013Publication date: December 4, 2014Inventors: Stefan Schulte, Thomas Weimer, Kay Hofmann
-
Publication number: 20140356871Abstract: The disclosure relates to the field of human genetics, particularly the field of peripheral neuropathy, particularly inherited peripheral neuropathy. Specifically, the disclosure relates to methods and materials to detect hereditary peripheral neuropathy, more particularly autosomal recessive Charcot-Marie-Tooth disease.Type: ApplicationFiled: January 10, 2013Publication date: December 4, 2014Applicant: VIB VZWInventors: Albena Jordanova, Magdalena Zimon, Jonathan Baets, Peter De Jonghe
-
Publication number: 20140356944Abstract: The present disclosure provides engineered transaminase polypeptides having improved properties as compared to naturally occurring transaminases including the ability of converting the substrate, 3?-hydroxyacetophenone to (S)-3-(1-aminoethyl)-phenol in enantiomeric excess and high percentage conversion. Also provided are polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to synthesize (S)-3-(1-aminoethyl)-phenol and related compounds useful in the production of active pharmaceutical ingredients.Type: ApplicationFiled: August 19, 2014Publication date: December 4, 2014Inventors: Fabien Louis Cabirol, Anupam Gohel, Seong Ho Oh, Derek J. Smith, Brian Wong, James J. Lalonde
-
Publication number: 20140356347Abstract: The present disclosure provides novel variants of enzymes exhibiting serine protease activity; nucleic acid molecules encoding said proteases, vectors, host cells containing the nucleic acids and methods for preparation and producing such enzymes; compositions and complexes comprising at least one of the proteases; and methods for using such enzymes as a part of an immunoprotease, in particular for the treatment of cancer.Type: ApplicationFiled: September 21, 2012Publication date: December 4, 2014Inventors: Stefan Barth, Sonja Schiffer, Grit Hehmann-Titt
-
Publication number: 20140348817Abstract: Methods and diagnostic agents for identification of subjects for cancer treatment with an anti-hyaluronan agent, such as a hyaluronan-degrading enzyme, are provided. Diagnostic agents for the detection and quantification of hyaluronan in a biological sample and monitoring cancer treatment with an anti-hyaluronan agent, for example a hyaluronan-degrading enzyme, are provided. Combinations and kits for use in practicing the methods also are provided.Type: ApplicationFiled: August 14, 2014Publication date: November 27, 2014Inventors: Ping Jiang, H. Michael Shepard, Lei Huang
-
Publication number: 20140342401Abstract: The present invention relates to a transfected mammalian host cell whose ability to secrete a foreign protein has been enhanced by using a foreign gene expression vector having a promoter derived from a human gene, and a method for producing the foreign protein using the host cell. A method for enhancing the production of a foreign protein to be used in a pharmaceutical protein product in a host cell such as a cultured mammalian cell is provided. A promoter derived from a human gene having a promoter activity higher than that of a cytomegalovirus (CMV) promoter in a host cell such as a cultured mammalian cell is provided.Type: ApplicationFiled: May 28, 2014Publication date: November 20, 2014Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventor: Kenji Murakami
-
Publication number: 20140342412Abstract: The present disclosure relates to transaminase polypeptides capable of aminating a dicarbonyl substrate, and polynucleotides, vectors, host cells, and methods of making and using the transaminase polypeptides.Type: ApplicationFiled: September 7, 2012Publication date: November 20, 2014Applicant: CODEXIS, INC.Inventors: Fabien Cabirol, Haibin Chen, Anupam Gohel, Paulina Salim, Derek Smith, Jacob Janey, Birgit Kosjek, Weng Lin Tang, Helen Hsieh, Son Pham
-
Publication number: 20140335053Abstract: The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+ T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.Type: ApplicationFiled: May 22, 2014Publication date: November 13, 2014Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Rong-Fu Wang, Steven A. Rosenberg, Gang Zeng
-
Publication number: 20140336236Abstract: Novel ALK and NTRK1 fusion molecules and uses are disclosed.Type: ApplicationFiled: April 21, 2014Publication date: November 13, 2014Applicant: FOUNDATION MEDICINE, INC.Inventors: Maureen T. Cronin, Doron Lipson, Roman Yelensky
-
Publication number: 20140328875Abstract: Provided herein are chimeric influenza hemagglutinin (HA) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use.Type: ApplicationFiled: December 17, 2013Publication date: November 6, 2014Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Adolfo Garcia-Sastre, Peter Palese, Florian Krammer
-
Publication number: 20140329250Abstract: The invention provides calcium-binding photoproteins which can detect light emission with a higher sensitivity. The proteins of the invention comprising the amino acid sequence of SEQ ID NO: 2 can be used for the detection and measurement of calcium ions. The proteins of the invention are useful as reporter proteins, luminescent markers, etc. The polynucleotides of the invention are useful as reporter genes, etc.Type: ApplicationFiled: May 30, 2014Publication date: November 6, 2014Inventors: Satoshi INOUYE, Yuiko SAHARA